Clinical Trials Sponsored by Janssen, LP

Total 3090 results

Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study of Paliperidone Palmitate in Participants With Schizophrenia

Schizophrenia

Taiwan, Japan, Korea, Republic of
Janssen-Cilag S.p.A.

Completed

Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 Years

Schizophrenia
Janssen-Cilag, S.A.

Completed

FYS Study: Epidemiological, Multicentre, Cross-sectional Study in a Clinical Practice Environment, About the Relationship Between Functioning Status and the Quality of Sleep Perceived by Schizophrenic Outpatients in Spain

Schizophrenia
Janssen-Cilag, S.A.

Completed

Case-control Study- Cancer Pain: Uncontrolled Pain as Depression Development Predictor in Oncologic Patients (Fentanyl)

Cancer Pain
Janssen Cilag S.A.S.

Completed

Influence of Rabeprazole on the Magnitude of the Antiplatelet Action of Clopidogrel (CLARA)

Healthy
Janssen-Cilag B.V.

Completed

A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy

Neoplasms | Anemia
Janssen-Cilag, S.A.

Completed

ADH.E.R.E.: Therapeutic ADHerence and Treatment Strategies: A Mental Health Registry

Depression | Schizophrenia | Bipolar Disorder | Personality Disorder
Janssen Cilag S.A.S.

Completed

Effect of Early High-dose Epoetin Alfa During Cardiac Arrest (Pilot Study)

Cardiac Arrest | Resuscitation | Cardiopulmonary
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease.

Alzheimer Disease
Janssen Pharmaceutical K.K.

Completed

An Exploratory Study on the Safety and Effectiveness of Paliperidone in Patients With Schizophrenia

Schizophrenia
Janssen Pharmaceutical K.K.

Completed

Phase II Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Cancer Pain- Assessment of Effectiveness, Safety and Pharmacokinetics -

Pain, Intractable
Amber Graystone
Purdue Pharma LP

Unknown

Current Procedural Sedation Practices in a Canadian Community Emergency Department

Conscious Sedation

Canada
Janssen-Cilag Ltd.

Recruiting

Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients (REASON)

Crohn's Disease

Taiwan, Israel
Janssen-Cilag Ltd.

Recruiting

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials (REALiTEC/TAL)

Relapsed/Refractory Multiple Myeloma (RRMM)

France, Denmark, Israel, Spain, Italy, United Kingdom, Germany, Sweden
Janssen-Cilag Ltd.

Recruiting

A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide (ArtemisPRO)

Metastatic Hormone-sensitive Prostate Cancer

France, Germany, Spain, Greece, Austria, United Kingdom
Janssen Pharmaceutical K.K.

Recruiting

A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)

Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)

Taiwan, Korea, Republic of, Japan
UNICANCER
Janssen Pharmaceutica

Recruiting

Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy (CARLHA-2)

Prostate Cancer

France
Janssen Biotech, Inc.

Active, not recruiting

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Prostate Cancer | Prostatic Neoplasm

United States
Janssen Pharmaceutical K.K.

Active, not recruiting

A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma (YATAGARASU)

Salivary Gland Neoplasms

Japan
Janssen Biotech, Inc.

Active, not recruiting

An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis (OPAL)

Ulcerative Colitis

United States, France, Germany, Spain, Canada, Greece, Korea, Republic of, Austria, Czechia
Janssen Pharmaceutical K.K.

Terminated

A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments

Dermatomyositis | Polymyositis

Japan
Janssen-Cilag S.p.A.

Completed

A Study of Guselkumab in Naive or Bio-experienced Participants With Regional (Facial and Genital) Psoriasis (GULLIVER)

Psoriasis

Italy
Janssen-Cilag, S.A.

Completed

An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives

Depression

Mexico
Janssen-Cilag Ltd.

Terminated

Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis (G-CARE)

Psoriasis

Italy, Germany, Greece
Janssen Pharmaceutical K.K.

Terminated

A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)

Takayasu Arteritis

Japan
Janssen-Cilag Ltd.

Terminated

A Study to Evaluate the Impact of Care4Today® IBD, a Smart System to Facilitate the Management of Crohn's Disease by Patients and Health Care Providers

Crohn Disease

United Kingdom
Janssen Pharmaceutical K.K.

Terminated

A Study of JNJ-75220795 in Japanese Participants

Fatty Liver

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-77242113 in Healthy Japanese and Chinese Participants

Healthy

Japan
Janssen-Cilag Ltd.

Completed

Prospective Observational Study on Ustekinumab (Stelara) Assessing Efficacy and Healthcare Resource Utilization in Crohn's Disease (PROSE)

Crohn Disease

Sweden
Janssen-Cilag Ltd.

Completed

A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis (G-PLUS)

Psoriasis

Germany, France, Italy, Spain, United Kingdom
Janssen-Cilag S.p.A.

Completed

A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting (EVIdeNCE)

Leukemia, Lymphocytic, Chronic, B-Cell

Italy
Janssen Pharmaceutical K.K.

Completed

A Study of Ad26.COV2.S in Adults (COVID-19)

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-61393215 in Healthy Japanese Male Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Evaluate the Single Vaccination of an Adenovirus Serotype 26 Pre-Fusion F (Ad26.preF) Based Respiratory Syncytial Virus (RSV) Vaccine in Japanese Adults Aged 60 Years and Older

Healthy

Japan
Janssen-Cilag S.p.A.

Completed

An Italian Observation of Antiretroviral Treatment in Participants Taking Darunavir/ Cobicistat Plus Emtricitabine and Tenofovir Alafenamide Fumarate (DIAMANTE)

Human Immunodeficiency Virus (HIV)

Italy
Janssen Cilag S.A.S.

Completed

A Study to Characterize Profile of Participant With Psoriatic Arthritis Depending on Whether Their Disease is Managed by a Dermatologist or by a Rheumatologist, and Starting Ustekinumab (PROUST)

Psoriatic Arthritis

France
Janssen BioPharma, Inc.

Completed

A First-In-Human Study of Orally Administered JNJ-64417184 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses, and the Antiviral Activity of Multiple Doses in a Respiratory Syncytial Virus (RSV) Challenge Study in Healthy Participants

Healthy

United Kingdom
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Pustular Psoriasis

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-63733657 in Healthy Japanese Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis

Palmoplantar Pustulosis

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Guselkumab Following a Single Intravenous Administration in Healthy Japanese Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy

Metastatic Castration-Resistant Prostate Cancer

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Evaluate the Pharmacokinetics (PK) of Darunavir (DRV) and Cobicistat (COBI) After a Single Oral Administration of Darunavir/Cobicistat Fixed-Dose Combination in Healthy Japanese Adult Participants

Healthy

Japan
Janssen-Cilag S.p.A.

Completed

Study in HIV1-Positive, Virosuppressed Patients Currently inTreatment With Ritonavir-Boosted Protease Inhibitors (PI/r) Starting Cobicistat-Boosted Darunavir (DRV/c - Rezolsta) (STORE)

Human Immunodeficiency Virus
Janssen Pharmaceutical K.K.

Completed

Phase 1 Study of Abiraterone Acetate in Castration-resistant Prostate Cancer

Prostatic Neoplasms

Japan
Janssen-Cilag Ltd.

Completed

Study to Describe the Actual Situation of Hepatitis C Treatment in Brazil (PICTURE)

Hepatitis C Virus

Brazil
Janssen Pharmaceutical K.K.

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-42847922 in Healthy Japanese Male Participants

Healthy

Japan
Janssen Diagnostics, LLC

Completed

Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index (COMETI P2)

Metastatic Breast Cancer

United States, Canada
Janssen Pharmaceutical K.K.

Withdrawn

A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of CR6261 in Japanese Healthy Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Japan

3

Subscribe